337 related articles for article (PubMed ID: 23637844)
1. In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma.
Veringa SJ; Biesmans D; van Vuurden DG; Jansen MH; Wedekind LE; Horsman I; Wesseling P; Vandertop WP; Noske DP; Kaspers GJ; Hulleman E
PLoS One; 2013; 8(4):e61512. PubMed ID: 23637844
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
3. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
[No Abstract] [Full Text] [Related]
4. Signaling pathways and mesenchymal transition in pediatric high-grade glioma.
Meel MH; Schaper SA; Kaspers GJL; Hulleman E
Cell Mol Life Sci; 2018 Mar; 75(5):871-887. PubMed ID: 29164272
[TBL] [Abstract][Full Text] [Related]
5. Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
Crotty EE; Leary SES; Geyer JR; Olson JM; Millard NE; Sato AA; Ermoian RP; Cole BL; Lockwood CM; Paulson VA; Browd SR; Ellenbogen RG; Hauptman JS; Lee A; Ojemann JG; Vitanza NA
J Neurooncol; 2020 Jul; 148(3):607-617. PubMed ID: 32556862
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.
Nagaraja S; Vitanza NA; Woo PJ; Taylor KR; Liu F; Zhang L; Li M; Meng W; Ponnuswami A; Sun W; Ma J; Hulleman E; Swigut T; Wysocka J; Tang Y; Monje M
Cancer Cell; 2017 May; 31(5):635-652.e6. PubMed ID: 28434841
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas.
Dorris K; Sobo M; Onar-Thomas A; Panditharatna E; Stevenson CB; Gardner SL; Dewire MD; Pierson CR; Olshefski R; Rempel SA; Goldman S; Miles L; Fouladi M; Drissi R
J Neurooncol; 2014 Mar; 117(1):67-76. PubMed ID: 24477622
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
[TBL] [Abstract][Full Text] [Related]
9. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma.
Lin GL; Nagaraja S; Filbin MG; Suvà ML; Vogel H; Monje M
Acta Neuropathol Commun; 2018 Jun; 6(1):51. PubMed ID: 29954445
[TBL] [Abstract][Full Text] [Related]
10. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.
Barrow J; Adamowicz-Brice M; Cartmill M; MacArthur D; Lowe J; Robson K; Brundler MA; Walker DA; Coyle B; Grundy R
Neuro Oncol; 2011 Feb; 13(2):212-22. PubMed ID: 21138945
[TBL] [Abstract][Full Text] [Related]
11. Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?
Hargrave D
CNS Oncol; 2012 Nov; 1(2):137-48. PubMed ID: 25057864
[TBL] [Abstract][Full Text] [Related]
12. A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent.
Halvorson KG; Barton KL; Schroeder K; Misuraca KL; Hoeman C; Chung A; Crabtree DM; Cordero FJ; Singh R; Spasojevic I; Berlow N; Pal R; Becher OJ
PLoS One; 2015; 10(3):e0118926. PubMed ID: 25748921
[TBL] [Abstract][Full Text] [Related]
13. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
[TBL] [Abstract][Full Text] [Related]
14. Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG).
Gwak HS; Park HJ
Crit Rev Oncol Hematol; 2017 Dec; 120():111-119. PubMed ID: 29198324
[TBL] [Abstract][Full Text] [Related]
15. Design considerations of an IL13Rα2 antibody-drug conjugate for diffuse intrinsic pontine glioma.
Lian X; Kats D; Rasmussen S; Martin LR; Karki A; Keller C; Berlow NE
Acta Neuropathol Commun; 2021 May; 9(1):88. PubMed ID: 34001278
[TBL] [Abstract][Full Text] [Related]
16. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma.
Zhou Z; Luther N; Ibrahim GM; Hawkins C; Vibhakar R; Handler MH; Souweidane MM
J Neurooncol; 2013 Feb; 111(3):257-64. PubMed ID: 23232807
[TBL] [Abstract][Full Text] [Related]
17. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
Deligne C; Hachani J; Duban-Deweer S; Meignan S; Leblond P; Carcaboso AM; Sano Y; Shimizu F; Kanda T; Gosselet F; Dehouck MP; Mysiorek C
Fluids Barriers CNS; 2020 Jun; 17(1):37. PubMed ID: 32487241
[TBL] [Abstract][Full Text] [Related]
18. Repurposing Vandetanib plus Everolimus for the Treatment of
Carvalho DM; Richardson PJ; Olaciregui N; Stankunaite R; Lavarino C; Molinari V; Corley EA; Smith DP; Ruddle R; Donovan A; Pal A; Raynaud FI; Temelso S; Mackay A; Overington JP; Phelan A; Sheppard D; Mackinnon A; Zebian B; Al-Sarraj S; Merve A; Pryce J; Grill J; Hubank M; Cruz O; Morales La Madrid A; Mueller S; Carcaboso AM; Carceller F; Jones C
Cancer Discov; 2022 Feb; 12(2):416-431. PubMed ID: 34551970
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.
Broniscer A; Jia S; Mandrell B; Hamideh D; Huang J; Onar-Thomas A; Gajjar A; Raimondi SC; Tatevossian RG; Stewart CF
Pediatr Blood Cancer; 2018 Jul; 65(7):e27035. PubMed ID: 29512900
[TBL] [Abstract][Full Text] [Related]
20. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
J Neurosurg Pediatr; 2021 Aug; 28(4):371-379. PubMed ID: 34359048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
